0000902664-26-002553.txt : 20260515 0000902664-26-002553.hdr.sgml : 20260515 20260515170904 ACCESSION NUMBER: 0000902664-26-002553 CONFORMED SUBMISSION TYPE: SCHEDULE 13G/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20260515 DATE AS OF CHANGE: 20260515 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: Taysha Gene Therapies, Inc. CENTRAL INDEX KEY: 0001806310 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences EIN: 843199512 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SCHEDULE 13G/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-91724 FILM NUMBER: 26989663 BUSINESS ADDRESS: STREET 1: 3000 PEGASUS PARK DRIVE STREET 2: SUITE 1430 CITY: DALLAS STATE: TX ZIP: 75247 BUSINESS PHONE: (214) 612-0000 MAIL ADDRESS: STREET 1: 3000 PEGASUS PARK DRIVE STREET 2: SUITE 1430 CITY: DALLAS STATE: TX ZIP: 75247 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: Vestal Point Capital, LP CENTRAL INDEX KEY: 0001974915 ORGANIZATION NAME: EIN: 922296021 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SCHEDULE 13G/A BUSINESS ADDRESS: STREET 1: 632 BROADWAY STREET 2: SUITE 602 CITY: NEW YORK STATE: NY ZIP: 10012 BUSINESS PHONE: 6469894000 MAIL ADDRESS: STREET 1: 632 BROADWAY STREET 2: SUITE 602 CITY: NEW YORK STATE: NY ZIP: 10012 SCHEDULE 13G/A 1 primary_doc.xml X0202 SCHEDULE 13G/A 0000902664-26-001081 0001974915 XXXXXXXX LIVE 1 Common Stock, par value $0.00001 per share 03/31/2026 0001806310 Taysha Gene Therapies, Inc. 877619106 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TX 75247 Rule 13d-1(b) Vestal Point Capital, LP DE 0.00 18000000.00 0.00 18000000.00 18000000.00 N 6.3 IA PN Ryan Wilder X1 0.00 18000000.00 0.00 18000000.00 18000000.00 N 6.3 HC IN Taysha Gene Therapies, Inc. 3000 Pegasus Park Drive, Suite 1430, Dallas, Texas 75247. This statement is filed by: (i) Vestal Point Capital, LP (the "Investment Manager"), a Delaware limited partnership, and the investment adviser to a certain fund and a managed account (the "Vestal Point Fund and Account"), with respect to the shares of common stock, par value $0.00001 per share (the "Common Stock"), of Taysha Gene Therapies, Inc. (the "Company") directly held by the Vestal Point Fund and Account; and (ii) Mr. Ryan Wilder ("Mr. Wilder"), the Chief Investment Officer and Managing Partner of the Investment Manager and the Managing Member of Vestal Point Capital, LLC, the general partner of the Investment Manager, with respect to the shares of Common Stock directly held by the Vestal Point Fund and Account. The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons." The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Securities Exchange Act of 1934, the beneficial owner of the securities reported herein. The address of the business office of each of the Reporting Persons is 632 Broadway, Suite 602, New York, NY 10012. The Investment Manager is a Delaware limited partnership. Mr. Wilder is a citizen of the United States. N IA HC The information required by Item 4(a) is set forth in Row 9 of the cover page for each of the Reporting Persons and is incorporated herein by reference. The percentage set forth in this Schedule 13G is calculated based upon an aggregate of 287,269,885 shares of Common Stock outstanding as of March 19, 2026, as reported in the Company's Annual Report on the Form 10-K for the fiscal year ended December 31, 2025, filed with the Securities and Exchange Commission on March 19, 2026. 6.3% The information required by Item 4(c)(i) is set forth in Row 5 of the cover page for each of the Reporting Persons and is incorporated herein by reference. The information required by Item 4(c)(ii) is set forth in Row 6 of the cover page for each of the Reporting Persons and is incorporated herein by reference. The information required by Item 4(c)(iii) is set forth in Row 7 of the cover page for each of the Reporting Persons and is incorporated herein by reference. The information required by Item 4(c)(iv) is set forth in Row 8 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Y N See Item 2(a). The Vestal Point Fund and Account have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the shares of Common Stock reported herein. Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. Vestal Point Capital, LP /s/ Ryan Wilder 05/15/2026 Ryan Wilder /s/ Ryan Wilder 05/15/2026